Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind phase II study of SHR-2017 injection in patients with bone metastases from solid tumors
CTR20252302Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2017 in bone metastases, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jun 2025; status: active.
02
Drugs
SHR-2017
03
Conditions
bone metastases
Beyond the preview
Go deeper on CTR20252302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252302.